New research published in Nature Communications reveals that primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) involve distinct colonic mucosal topographies, despite sharing common immune cell programs during active disease. According to the study by Tearle et al. (2026), identifying these biological differences is essential for developing precision therapies for patients suffering from PSC-associated ulcerative colitis (PSC-UC).
Biological Differences Between PSC-UC and UC
While PSC-UC often presents similarly to conventional ulcerative colitis, clinical markers distinguish the two conditions. Patients with PSC-UC typically experience less severe disease flares compared to those with standard UC. However, these patients face a higher lifetime risk of developing colorectal cancer. Research conducted by Tearle et al. highlights that the fundamental biology of these conditions differs significantly at the mucosal level.
Did you know?
PSC-UC is characterized by a right-sided colonic predominance, a distinct anatomical pattern that differentiates it from the distribution often seen in traditional ulcerative colitis cases.
Microbial Communities and Immune Cell Enrichment
To understand why these diseases progress differently, researchers analyzed biopsies from four distinct colon regions. Using single-cell mRNA sequencing, antigen receptor sequencing, and spatial transcriptomics, the study identified unique, mucosal-adherent microbial communities in PSC-UC patients. These communities are not only different from healthy controls but are also specific to certain regions of the colon.
The study also observed an enrichment of activated CD8 T cells and γδ T cells in the right colon of PSC-UC patients. Notably, this immune activity occurred even in the absence of histological inflammation, suggesting that the immune system is primed for response long before physical damage becomes visible under a microscope.
The Role of TMEM176B+ Mast Cells in Disease Relapse
Despite their distinct topographies, PSC-UC and UC share specific cellular pathways when the disease becomes active. Researchers identified a population of TMEM176B+ mast cells that appears to be pro-tumorigenic. This specific cell population becomes enriched in the colon during disease relapse across both PSC-UC and UC cohorts.
According to the findings, this shared mast cell state suggests that while the “map” of the disease—the mucosal topography—is different, the “engine” driving the relapse may rely on similar cellular mechanisms. This insight provides a clear target for future therapeutic development.
Future Trends in Precision Gastroenterology
The ability to distinguish between PSC-UC and UC at a molecular level is shifting the focus toward precision medicine. By identifying which patients harbor specific microbial communities or immune cell profiles, clinicians may soon be able to tailor treatments to the individual rather than applying a one-size-fits-all approach to inflammatory bowel disease management.
Frequently Asked Questions
- How is PSC-UC different from standard UC?
PSC-UC typically features right-sided colonic predominance, less severe flares, and a higher lifetime risk of colorectal cancer compared to UC alone. - What are TMEM176B+ mast cells?
These are a specific population of immune cells identified by researchers as being enriched during disease relapse; they are believed to have pro-tumorigenic properties. - Can these findings help with treatment?
Yes. By understanding the unique mucosal topography and shared immune programs, researchers aim to develop more targeted, precision therapies for PSC-UC patients.
Have you or a loved one been diagnosed with PSC-IBD? Share your experiences in the comments below or subscribe to our newsletter for the latest updates on digestive health research.
Keep reading